Efficacy, onset of action and tolerability of moxifloxacin in patients with community-acquired pneumonia: Results of a postmarketing surveillance study

Clinical Drug Investigation

Volumn 21, Issue 12, 2001, Pages 801-811

  Landen, Harald ^a   Bauer, Torsten ^b  

^a BAYER AG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0035690038     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121120-00002     Document Type: Article

References (46)

1. Deaths: Final data for 1999
2. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America
3. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention
4. The cost of treating community-acquired pneumonia
5. BTS guidelines for the management of chronic obstructive pulmonary disease
6. Quality of care, process, and outcomes in elderly patients with pneumonia
7. Practical considerations and guidelines for the management of community-acquired pneumonia
8. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland
9. Epidemiology of respiratory tract infections
10. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: Results of a national surveillance study
11. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
12. Comparison of the antibacterial activities of the quinolones Bay 12- 8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
13. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone
14. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens
15. Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae
16. BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens
17. Moxifloxacin: A comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae
18. Susceptibility of penicillin-resistant and penicillin-susceptible Streptococcus pneumoniae to newer antimicrobial agents
19. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests
20. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms
21. Pharmacodynamic activity of moxifloxacin in an in vitro model against Gram-positive and Gram-negative pathogens
22. Penetration of Bay 12-8039 into bronchial mucosa, epithelial lining
23. Penetration of moxifloxacin into peripheral compartments in humans
24. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia
25. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia
26. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia
27. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild- to-moderate, community-acquired, suspected pneumococcal pneumonia in adults
28. Reassuring safety profile of moxifloxacin
29. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin
30. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: A multicenter study
31. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States
32. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995
33. Prevalence of antibiotic resistance among European respiratory tract pathogens (1999/2000)
34. Penicillin-resistant Streptococcus pneumoniae: Review of moxifloxacin activity
35. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States
36. The QT interval
37. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes
38. Safety update of moxifloxacin: A current review of clinical trials and worldwide post-marketing observational study
39. A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis
40. Moxifloxacin in acute exacerbations of chronic bronchitis: Clinical evaluation and assessment by patients
41. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis; a Spanish physician and patient experience
42. Short-course (5-day) moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitis
43. Treatment outcomes in acute exacerbations of chronic bronchitis: Comparison of macrolides and moxifloxacin from the patient perspective
44. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: A primary care experience